Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe.
作者信息
Cave Alison, Kurz Xavier, Arlett Peter
机构信息
Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.
出版信息
Clin Pharmacol Ther. 2019 Jul;106(1):36-39. doi: 10.1002/cpt.1426. Epub 2019 Apr 10.
Abstract
摘要
相似文献
1
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe.用于监管决策的真实世界数据：欧洲面临的挑战与可能的解决方案
Clin Pharmacol Ther. 2019 Jul;106(1):36-39. doi: 10.1002/cpt.1426. Epub 2019 Apr 10.
2
The US Food and Drug Administration's Real-World Evidence Framework: A Commitment for Engagement and Transparency on Real-World Evidence.美国食品药品监督管理局的真实世界证据框架：对真实世界证据的参与和透明度的承诺。
Clin Pharmacol Ther. 2019 Jul;106(1):33-35. doi: 10.1002/cpt.1389. Epub 2019 Mar 18.
3
Advances in the Use of Real-World Evidence for Medical Devices: An Update From the National Evaluation System for Health Technology.医疗器械真实世界证据的应用进展：来自国家卫生技术评估系统的最新情况
Clin Pharmacol Ther. 2019 Jul;106(1):30-33. doi: 10.1002/cpt.1380. Epub 2019 Mar 19.
4
Information Patients Can Provide Will Strengthen the Real-World Evidence That Matters to Them.患者能够提供的信息将强化对他们至关重要的真实世界证据。
Clin Pharmacol Ther. 2019 Jul;106(1):49-51. doi: 10.1002/cpt.1460. Epub 2019 May 21.
5
Real-World Evidence of Treatment Effects: The Useful and the Misleading.治疗效果的真实世界证据：有用的与误导性的。
Clin Pharmacol Ther. 2019 Jul;106(1):43-44. doi: 10.1002/cpt.1405. Epub 2019 Apr 3.
6
Decentralized Trials in the Age of Real-World Evidence and Inclusivity in Clinical Investigations.真实世界证据时代的去中心化试验与临床研究中的包容性
Clin Pharmacol Ther. 2019 Jul;106(1):25-27. doi: 10.1002/cpt.1441. Epub 2019 Apr 23.
7
Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.药品监管中使用患者登记系统的障碍与机遇
Clin Pharmacol Ther. 2019 Jul;106(1):39-42. doi: 10.1002/cpt.1414. Epub 2019 Apr 10.
8
Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety Surveillance.真实世界数据、高级分析与上市后药品安全监测的演变
Clin Pharmacol Ther. 2019 Jul;106(1):28-30. doi: 10.1002/cpt.1415. Epub 2019 Apr 8.
9
EU agrees tighter standards for medical devices.欧盟同意收紧医疗器械标准。
BMJ. 2016 Jun 1;353:i3058. doi: 10.1136/bmj.i3058.
10
Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.收集、获取和评估接受膳食补充剂患者的上市后监测不良事件报告系统（AERS）数据时面临的挑战。
Thromb Res. 2005;117(1-2):137-44; discussion 145-51. doi: 10.1016/j.thromres.2005.07.005. Epub 2005 Sep 1.
引用本文的文献
1
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024.上市后措施中包含的真实世界数据：2013年至2024年欧盟批准的高级治疗药品案例研究
BioDrugs. 2025 Aug 26. doi: 10.1007/s40259-025-00737-x.
2
Advancing Real-World Evidence Through a Federated Health Data Network (EHDEN): Descriptive Study.通过联合健康数据网络（EHDEN）推进真实世界证据：描述性研究。
J Med Internet Res. 2025 Aug 7;27:e74119. doi: 10.2196/74119.
3
Real-time data in cancer registries: Validation of an automated data extraction system.癌症登记处的实时数据：自动数据提取系统的验证
iScience. 2025 Jul 3;28(8):113056. doi: 10.1016/j.isci.2025.113056. eCollection 2025 Aug 15.
4
Current and future perspective of registry utilisation for regulatory settings in Japan: pharmaceuticals, medical devices, and regenerative medicine products.日本监管环境下注册登记利用的现状与未来展望：药品、医疗器械和再生医学产品
J Pharm Policy Pract. 2025 Jul 4;18(1):2523935. doi: 10.1080/20523211.2025.2523935. eCollection 2025.
5
Use of real-world data as pivotal evidence in veterinary regulatory applications.在兽医监管应用中使用真实世界数据作为关键证据。
Front Vet Sci. 2025 Jun 18;12:1588068. doi: 10.3389/fvets.2025.1588068. eCollection 2025.
6
[What can registries contribute to health services research?].登记处对卫生服务研究能有哪些贡献？
Pravent Gesundh. 2022 Aug 22:1-6. doi: 10.1007/s11553-022-00969-7.
7
Data, dialogue, and design: patient and public involvement and engagement for natural language processing with real-world cancer data.数据、对话与设计：患者及公众参与和融入真实世界癌症数据的自然语言处理
Front Digit Health. 2025 May 15;7:1560757. doi: 10.3389/fdgth.2025.1560757. eCollection 2025.
8
Advancements in Electronic Medical Records for Clinical Trials: Enhancing Data Management and Research Efficiency.临床试验电子病历的进展：提高数据管理和研究效率。
Cancers (Basel). 2025 May 2;17(9):1552. doi: 10.3390/cancers17091552.
9
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms.真实世界证据在法国、德国、意大利、西班牙和英国卫生技术决策中的作用与价值：关于外部对照臂的见解
Int J Technol Assess Health Care. 2025 Apr 22;41(1):e25. doi: 10.1017/S0266462324004720.
10
Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.自发报告与纵向医疗保健数据库在信号管理中的相互作用：国际药物警戒协会真实世界证据与大数据特别兴趣小组的立场声明
Drug Saf. 2025 Apr 13. doi: 10.1007/s40264-025-01548-3.
本文引用的文献
1
Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.欧洲的电子医疗保健数据库：特征描述及在药品监管中的应用潜力分析
BMJ Open. 2018 Sep 5;8(9):e023090. doi: 10.1136/bmjopen-2018-023090.
2
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?数据丰富，信息匮乏：我们能否利用电子健康记录为制药行业创建学习型医疗保健系统？
Clin Pharmacol Ther. 2019 Apr;105(4):912-922. doi: 10.1002/cpt.1226. Epub 2018 Oct 14.
3
The use of real-world data in cancer drug development.真实世界数据在癌症药物研发中的应用。
Eur J Cancer. 2018 Sep;101:69-76. doi: 10.1016/j.ejca.2018.06.036. Epub 2018 Jul 18.
4
Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.研究设计和风险最小化措施评估：对向欧洲药品管理局提交的心血管、内分泌和代谢药物研究的综述。
Drug Saf. 2018 Feb;41(2):191-202. doi: 10.1007/s40264-017-0604-4.
5
Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.衡量药品监管干预措施的影响——系统评价及方法学考虑。
Br J Clin Pharmacol. 2018 Mar;84(3):419-433. doi: 10.1111/bcp.13469. Epub 2017 Dec 20.
6
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.报告以提高医疗保健数据库研究的可重复性并促进有效性评估V1.0版
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1018-1032. doi: 10.1002/pds.4295.
7
Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.促进和保护公众健康：欧盟药物警戒系统如何运作
Drug Saf. 2017 Oct;40(10):855-869. doi: 10.1007/s40264-017-0572-8.
8
Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study.在一项III期真实世界有效性试验中监测安全性：索尔福德肺部研究中新型方法的应用。
Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):344-352. doi: 10.1002/pds.4118. Epub 2016 Nov 1.
9
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.ROBINS-I：一种评估干预性非随机研究偏倚风险的工具。
BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919.
10
Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project.采用通用方案的多中心、多数据库研究：从IMI PROTECT项目中汲取的经验教训。
Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:156-65. doi: 10.1002/pds.3968.
Zotero 插件